BIOCON, Author at Biocon

Leaving the Biocon site!

You are now leaving the Biocon website for a Biocon affiliate site or third party site that is solely responsible for its content, including its compliance with guidelines applicable in certain geographies. Links to Biocon affiliate sites and third party sites are provided as a resource to our visitors and may not be governed by the same regulatory requirements applicable to this site and unaffiliated third party sites are subject to their own terms and data protection notices and practices. Moreover, if their third party site is subject to other country laws, regulatory requirements, data protection requirements or medical practices may differ between countries and the information provided therein may not be suitable for use in your country.

U.S. FDA Completes Two cGMP Inspections at Biocon Biologics Insulins Facility in Malaysia

Biocon Biologics Expands Footprint in Emerging Markets Takes Over the Commercialization of Biosimilars Business from Viatris in 70+ countries

After Five Years of Successful Experience Internationally, Biocon Biologics’ Hulio® Biosimilar to Humira®, Now Available in the United States

Biocon Group concluded the month-long sustainability initiatives commemorating ‘World Environment Day’ initiated with ‘Nature Positive’ Campaign

Biocon’s API manufacturing facility in Bangalore receives EU GMP compliance certificate

Biocon Pharma Limited’s facility at Bengaluru Concludes USFDA Surveillance and Inspection, With Zero Observations

Biocon Q4FY23 Revenue at Rs 3,929 Cr, Up 59%; Biosimilars Up 114%; Research Services Up 31%

Biocon’s API facility at Hyderabad Concludes USFDA Inspection, with Zero Observations

Biocon Biologics’ New mAbs Facility Receives EU GMP Certification for bBevacizumab

Serum & Biocon Biologics Agree to Restructure Equity Investment